Please login to order a test.
Evaluate toxicity; monitor therapeutic levels
Liquid chromatography/tandem mass spectrometry (LC/MS-MS)
Therapeutic: 25−104 μg/mL; steady-state trough levels are dose proportional in adults. Multiple daily doses of 1200, 2400, and 3600 mg/day gave trough levels of 25−35, 47−63, and 62−104 μg/mL, respectively. Steady-state peak concentrations are dose proportional in children ages 4 to 12 years over a range of 15, 30, 45 mg/kg/day. The dose proportional peak concentrations were reported as 17, 32, and 49 μg/mL, respectively at two to six hours postdose. Co-administration of carbamazepine, phenytoin, phenobarbital, or primidone can cause a decrease in felbamate plasma concentrations; conversely, valproic acid can increase concentrations.1 In children, a similar effect was found with carbamazepine and phenytoin decreasing levels and an opposite effect with valproic acid.2
Following oral administration, felbamate is 25% bound to serum albumin. Approximately 40% to 50% of the absorbed dose appears unchanged in the urine. The rest is present as nonactive metabolites, including parahydroxyfelbamate, 2-hydroxyfelbamate, and felbamate monocarbamate. Felbamate has an elimination half-life of 20 to 23 hours. The apparent volume of distribution is 0.7−1.0 L/kg.
Serum or plasma
Red-top tube, lavender-top (EDTA) tube, or green-top (heparin) tube. Do not use a gel-barrier tube. The use of gel-barrier tubes is not recommended due to slow absorption of the drug by the gel. Depending on the specimen volume and storage time, the decrease in drug level due to absorption may be clinically significant.
Transfer separated serum or plasma to a plastic transport tube.
Causes for Rejection
|Order Code||Order Code Name||Order Loinc||Result Code||Result Code Name||UofM||Result LOINC|
|716530||Felbamate (Felbatol(R)), Serum||6899-9||716531||Felbamate, Serum||ug/mL||6899-9|